Allogeneic Hematopoietic Progenitor Cell Therapy
Customize your policy alerts
Sign up for Centene Policy CP.MP.249 alerts
Get alerted when Policy CP.MP.249 changes without checking for updates manually.
Monitor payer policy activity
Medical necessity criteria for use of Omisirge (omidubicel) and RegeneCyte (HPC Cord Blood) for non‑Medicare Centene-affiliated health plans; who may qualify and under what conditions.
RegeneCyte (HPC Cord Blood) criteria were added to the policy as Criteria II.
Criteria I updated to include severe aplastic anemia as a medically necessary indication for Omisirge.
Added note referring Medicare criteria to separate Medicare policy MC.CP.MP.249 and specified 'non‑Medicare' health plans.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.